Despite being a ubiquitous animal pain model, the natural TRPA1-agonist allyl isothiocyanate (AITC, also known as "mustard oil") has only been sparsely investigated as a potential human surrogate model of pain, sensitization, and neurogenic inflammation. Its dose-response as an algogenic, sensitizing irritant remains to be elucidated in human skin. Three concentrations of AITC (10%, 50%, and 90%) and vehicle (paraffin) were applied for 5 minutes to 3 3 3 cm areas on the volar forearms in 14 healthy volunteers, and evoked pain intensity (visual analog scale 0-100 mm) and pain quality were assessed. In addition, a comprehensive battery of quantitative sensory tests was conducted, including assessment of mechanical and thermal sensitivity. Neurogenic inflammation was quantified using full-field laser perfusion imaging. Erythema and hyperpigmentation were assessed before, immediately after, and 64 hours after AITC exposure. AITC induced significant dose-dependent, moderate-to-severe spontaneous burning pain, mechanical and heat hyperalgesia, and dynamic mechanical allodynia (P , 0.05). No significant differences in induced pain hypersensitivity were observed between the 50% and 90% AITC concentrations. Acute and prolonged inflammation was evoked by all concentrations, and assessments by full-field laser perfusion imaging demonstrated a significant dose-dependent increase with a ceiling effect from 50% to 90%. Topical AITC application produces pain and somatosensory sensitization in a dose-dependent manner with optimal concentrations recommended to be .10% and #50%. The model is translatable to humans and could be useful in pharmacological proof-of-concept studies of TRPA1-antagonists, analgesics, and anti-inflammatory compounds or for exploratory clinical purposes, eg, loss-or gain-of-function in peripheral neuropathies.
Introduction
The natural transient receptor potential cation channel A1 (TRPA1)-agonist allyl isothiocyanate (AITC), also known as "mustard oil" has been used ubiquitously as an in vivo pain model in hundreds of preclinical studies. 8, 16, 17, 45, 54 It generates inflammation and spontaneous pain behavior as well as robust thermal and mechanical hyperalgesia. 31, 35, 66 After cutaneous application, this symptomatology is evoked through activation of TRPA1-positive epidermal C-nociceptors. Notably, several additional animal pain models beyond AITC application per se rely partly or entirely on TRPA1 as their substrate, eg, models using formalin and trans-cinnamaldehyde. 21, 54, 82 The physiological role of TRPA1 in the sensory nervous system is not only restricted to chemonociception 39, 47, 53, 60 ; the channel has also been suggested to play important roles in mediating cold pain sensation, 6, 23, 80 pruriception, 28, 46, 84 the cough reflex, 24, 64 and to act as an immunological coactivator. 15, 69 The TRPA1-channel is substantially coexpressed with transient receptor potential cation channel V1 (TRPV1) on peptidergic nociceptors, 34 and these frequently act in conjunction to detect numerous environmental chemical irritants although it is currently unclear to which extent they are functionally dependent on each other. 22, 70, 79 Recently, TRPA1 has been implicated in a number of painful and inflammatory conditions and is considered a promising potential target for the development of, amongst others, analgesic, antipruritic and anti-inflammatory pharmacotherapeutics. 4, 21, 36, 64 For instance, the channel has been proposed to play a role in the pathoetiology of numerous pain disorders based on in vivo studies, including neuropathic pain, 9 migraine, 11 and arthritis, 29 and expression of the channel has been found upregulated in human tissues in conditions, such as oral lichen planus, 40 postburn pruritus, 85 and inflammatory bowel disorder 41 -conditions that are often associated with neuroinflammation and pain. In line with these observations, a number of TRPA1-antagonists are currently being developed to target such conditions. 4, 12, 21, 36, 64 Despite its very widespread usage as a model of TRPA1-induced pain and inflammation in animals, the AITC-model has not been extensively studied in humans. 25, 37, 38, 83 The few previous studies applying topical AITC in humans predate the discovery of TRPA1 and mainly assessed certain aspects of the somatosensory aberrations or neuronal events induced by AITC. 25, 37, 38, 75, 83 Dose-response features of this model have not previously been investigated. Given the difficulty and high failure rate associated with turning preclinical findings on promising antinociceptive and antihyperalgesic compounds into feasible analgesics for human use, 54 translatable mechanismspecific human surrogate models of pain, such as the AITC model, are warranted, 5, 63 and it is thus necessary to have dose-response information for the sensitization features of interest. Moreover, AITC might constitute a relevant receptorspecific pain provocation test, which could be applied to gain insights into pain mechanisms eg, loss-or gain-of-function in patients with neuropathic pain. 33, 57 The aim of this study was to assess the dose-response features of topical AITC provocations on evoked pain and painassociated sensory aberrations. Beyond evaluating evoked pain intensity and quality, a comprehensive battery of quantitative sensory tests was conducted together with the evaluation of neurogenic inflammatory responses.
Methods

Study design and subjects
Fourteen healthy subjects, including 10 men and 4 women, aged 19 to 28 years (mean 6SD: 23.5 6 3.1 years), were recruited. The subjects were pain free, without previous known neurological, dermatological, allergic, or musculoskeletal disorders. All subjects signed a statement of informed consent in accordance with the Helsinki Declaration before participation. The regional ethics committee approved the experiment (study no. N-20160066). Before the onset of the experiment, all subjects were instructed verbally and in writing that all experimental procedures could be stopped immediately if the pain or discomfort became intolerable, as well as that they are free to withdraw from the study at any point without incurring consequences. The study was performed in a double-blinded manner with balanced randomization of both the order of AITC applications, the application sites within each volar forearm (proximal vs distal locations), and dominant vs nondominant arm. Randomization of right vs left arms was done under the condition that arms always shifted between the applied solutions. Both the investigator and the subjects were blinded to the AITC concentration and vehicle being applied. Every time a substance was administered, a bottle of pure 99% AITC was opened in the laboratory. This was done to create a powerful ambient smell of mustard oil, to inhibit the investigator and participants' ability to identify the order of solutions investigated, by olfaction. A similar procedure has previously been used in studies using highly odorous compounds to avoid unmasking of subjects and investigators. 26, 58, 61 The study was conducted as a single session lasting approximately 2.25 to 3 hours, wherein the participants were exposed to all 4 solutions, interspersed with short breaks after each panel of sensory testing (Fig. 1) . The ambient temperature was kept at 21 to 22˚C in all sessions.
Application of allyl isothiocyanate
AITC ($99%) was obtained from Sigma-Aldrich (Broendby, Denmark) and dissolved in pure paraffin (European Pharmacopoeia; Løve-Apoteket, Aalborg, Denmark) at concentrations of 10%, 50%, and 90% (all vol/vol concentrations). These concentrations were determined by precedence in the literature showing that 100% AITC evokes a considerable pain and allodynia 38 and by initial pilot studies showing that much lower concentrations were likely sufficient to induce similar pain, hyperalgesia, and prominent neurogenic flare. Paraffin was chosen as the vehicle because of (1) its previous application for the purpose of applying AITC, (2) its lack of toxicity and irritant properties, (3) its lack of somatosensory effects. A 1-mL aliquot of each concentration was dispensed into a 3 3 3 cm cotton pad and placed in a custom-made polypropylene chamber (3 3 3 3 0.18 cm) (Aalborg University, Aalborg, Denmark). The chamber containing the cotton pad was then fixed to the premarked skin areas on the volar forearms using medical tape (BSN, Hamburg, Germany). With 2 premarked 3 3 3 cm areas on each volar forearm, the same skin areas were never reused. The 2 areas were 6 cm apart (each 3 cm away from the midpoint between the elbow and wrist creases) to assure Figure 1 . Flowchart of the study procedures. For each of the 4 substance applications, the assessments depicted were conducted. AITC, allyl isothiocyanate; ALL, allodynia; CDT, cold detection threshold; CPT, cold pain threshold; FLPI, full-field laser perfusion imaging; HPT, heat pain threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; NRS, numerical rating scale; VAS, visual analog scale; WDT, warmth detection threshold; WUR, wind-up ratio. Notice that the order of AITC/vehicle application was randomized.
nonoverlapping flare quantification. The application configuration was applied for 5 minutes before being carefully removed after which residual AITC/vehicle solution was gently washed of the skin. AITC was deliberately removed before proceeding, because initial pilot experiments indicated that if the skin area was not cleaned thoroughly, the induced pain would only subside slowly and increased hyperpigmentation would occur.
Pain assessment
For each concentration applied, the participants were instructed to rate the pain intensity for 5 minutes on a 100-mm visual analog scale (VAS) ranging from "no pain" 5 0, to "worst imaginable pain" 5 100. To this end, digital eVAS software (Aalborg University, Denmark) installed on a 10.10 Samsung tablet computer (Samsung Electronics, Seoul, Korea) was used, and the pain intensity was sampled at 0.2 Hz. Subjects expressed their pain quality by choosing word descriptors from a validated brief descriptive Danish version of the McGill Pain Questionnaire (MPQ). Pain quality was determined at 4 minutes after AITC application corresponding to a time point where moderate-tointense pain was perceived in most subjects. After the pain assessment, full-field laser perfusion imaging was conducted, and the subjects were asked to report when the pain subsided before proceeding with sensory testing.
Quantitative sensory testing
The QST battery of this study was partly derived from the guidelines of the German Research Network on Neuropathic Pain (DFNS). 68 The verbal instructions (in Danish) for participants from the DFNS protocol were derived from the supplementary materials of Olsen et al. (2014) . 61 The terminology used to describe the induced sensory derangement are defined in Sandkühler (2009). 71 
Thermal detection and pain thresholds
Tests for cold detection threshold, warmth detection threshold, cold pain threshold (CPT), and heat pain threshold (HPT) were performed using a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 3 3 cm advanced thermal stimulator probe with a baseline temperature of 32˚C. Ramping stimuli of 1˚C/s were delivered in each application area after AITC, and when the subjects identified the associated threshold (first perception of cold or warmth and first perception of cold or heat pain), they pressed a button that returned the temperature of the probe to the baseline at a rate of 5˚C/s. The results were calculated as the arithmetic mean of the thresholds from 3 repeated ramps.
Mechanical pain thresholds and sensitivity
To evaluate the mechanical pain threshold (MPT), a set of 7 weight-calibrated pinprick stimulators (MRC Systems, Germany) with weights of 8, 16, 32, 64, 128, 256 , and 512 mN was applied. During 5 ascending/descending series of stimuli, the subjects were instructed to report when a perception of "sharpness" or "pricking pain" was first sensed. The final MPT was calculated as the geometric mean of the values obtained in the 5 series of stimuli. The mechanical pain sensitivity (MPS) was assessed to detect pinprick hyperalgesia to suprathreshold stimulation. The 7 pinprick stimuli were applied in ascending order 3 times and for each stimulus, the subjects were instructed to rate the pain intensity on a numerical rating scale from 0 to 10 (0 5 no pain, 10 5 worst imaginable pain). Subjects were explicitly instructed to use decimals as suitable. The final MPS was calculated as the arithmetic mean of 3 consecutive series of the 7 stimuli. The windup ratio (WUR) was assessed using the pinprick stimulator one intensity above the average individual MPT. The subjects were asked to rate their pain intensity after a single stimulus and thereafter of a subsequent series of 10 consecutive stimuli (1 stimuli/second) applied within the area of substance application. This procedure was repeated 3 times.
Allodynia
Dynamic mechanical allodynia (ALL) was assessed using normally innocuous brush stimuli, conducted with a standardized sensory brush (SENSElab 05-brush; Somedic, Hörby, Sweden) exerting a force of 200 to 400 mN. It was always confirmed that subjects perceived the stimulation as nonpainful in an area at least 10 cm away from the relevant AITC-pretreated skin. Subsequently, the tactile stimulus was applied 3 times with a single stroke of approximately 3 cm in length within the AITCpretreated skin. The subjects were instructed to rate whether pain occurred and if so to rate the pain intensity on the same numerical rating scale used for MPS.
Neurogenic inflammatory response and pigmentation
Full-field laser perfusion imaging was used to assess the superficial blood perfusion immediately after removing the AITC/paraffin chamber. The measurements were conducted using a MoorFLPI-1 (Moor Instruments Ltd, Axminster, United Kingdom). The perfusion assessment was conducted with a 35-cm distance between the camera and the application area with an exposure time of 8.3 milliseconds and 160 units of gain. The full-field laser perfusion imaging data were analyzed using MoorFLPI Review V4.0 proprietary software. The induced increases in average and peak superficial blood perfusion within the 3 3 3 cm application areas were used as proxies for primary neurogenic inflammation intensity. Moreover, the axon-reflex flare size was calculated as the area associated with the AITC provocation exhibiting a $30% increase compared with the surrounding perfusion background. The size was quantified in square centimeters by relative comparison with the known size of the 3 3 3 cm premarked application area. The 9 cm 2 in which AITC was applied was then subtracted from the score, thus giving rise to an estimate of the size of the secondary neurogenic inflammation or "axon-reflex response." This method has previously been applied to quantify the neurogenic inflammatory response to various chemical irritants. 1, 2, 61 The erythema (redness) and skin pigmentation were measured with a spectrometer designed for cutaneous use (ColorMeter, DSM II; Cortex Technology, Hadsund, Denmark) as previously used. 56 The device provides a read-out of erythema and pigmentation based on the light absorption characteristics of skin for wavelength corresponding to hemoglobin (erythema) and melanin (pigmentation). Erythema and pigmentation data were recorded before, immediately after AITC removal, and 64 hours (48-96 hours range) after the experimental session.
Statistics
Sample size calculation was conducted based on previously obtained data applying similar pain models 61 and using the approached outlined for crossover designs. 56 The obtained data Data from all assessments were tested for normality using visual inspection of Q-Q plots and the Shapiro-Wilk normality test when necessary. Average and peak pain intensity induced by the AITC were calculated and compared from VAS recordings, whereas categorical variables are shown without further hypothesis testing. The primary analyses were conducted using repeated measures analyses of variance with the factor: concentration (4 levels) using Fisher least significant difference (LSD) test, post hoc test in a step-wise manner. For erythema and pigmentation data, an additional level of time was added to the repeated measures analyses of variance (3 timepoints), and values were always normalized to the values obtained from the vehicle area to account for day-to-day variability. Although all statistical tests were conducted using raw data, the temporal profiles of evoked pain ( Fig. 2A) were downscaled to one data point per 0.5 minutes by calculating the average of six 0.2 Hz ratings. Z scores were calculated to provide a relativized overview of induced sensory sensitization using the formula (Z 5 [x 2 m]/s), where "x" is the average value following AITC, "m" is the average value in the vehicle condition, and "s" is the combined SD for the parameter across the 4 solutions. Data handling and calculation of descriptive statistics were performed in Excel, whereas statistical comparisons were performed in SPSS (Both software packages: Windows, Redmond, WA), and graph plotting was conducted using GraphPad Prism. A P value #0.05 was considered significant.
Results
All enrolled participants finished the study, and topical administration of AITC was well tolerated and did not produce any unexpected side effects (eg, local edema, blistering, desquamation, or systemic reactions). No subjects withdrew from the study nor terminated any of the experimental procedures. The spontaneous pain evoked by AITC generally resolved quickly after removing residual solution and all subjects confirmed that no pain remained before the sensory testing was started. Because of technical issues, the erythema and pigmentation data are missing for one subject (excluded from those analyses, n 5 13). The study was designed to assess the dose-response function of AITC and not to detect potential sex differences in AITC-induced responses and hence, no subanalysis was conducted for this purpose. No significant differences were observed related to the order of AITC administration or arm dominancy.
Evoked pain intensity and quality
The most frequently reported descriptors of the evoked pain quality were "warm/burning" (10% n 5 5/14, 50% 5 10/14, 90% 5 10/14), "searing" (10% 5 8/14, 50%5 9/14, 90% 5 7/14), and pricking/stinging (10% 5 7/14, 50% 5 3/14, 90% 5 5/14). Four subjects described the vehicle as inducing a mild "cold/freezing" sensation. The mean pain intensity was dose-response dependent for both mean ratings and peak pain (F(3,39) 5 29.9, P , 0.001), see Figures 2A and B. Post hoc testing revealed that all AITC conditions induced more intense pain than the vehicle (P , 0.01), and that both 50% and 90% AITC induced higher pain intensity than 10% AITC (P , 0.01). This was true for both mean and peak pain ratings. No significant difference was found between 50% and 90% AITC. Peak pain intensity reached to 41.43 6 6.17 for 10% AITC, 56.9 6 7.77 for 50% AITC, and 59.9 6 7.46 for 90% AITC. Negligible pain was reported after vehicle application in 2 subjects who rated it on the VAS (both ,5 out of 100).
Thermal sensory sensitivity
Thermal cold and warmth detection thresholds remained unchanged after application of AITC, regardless of the concentration applied (F(3,39) 5 0.35, P . 0.7) and (F(3,39) 5 2.83, P . 0.05) indicating that neither thermal hypo-nor hyperesthesia was induced by AITC (Fig. 2C) . The CPT was, however, altered by AITC (F(3,39) 5 3.93, P , 0.05), with post hoc tests revealing that cold hypoalgesia was only significantly elicited in the 90% AITC condition (P , 0.05) compared with the vehicle. Conversely, HPT decreased significantly and in a dose-dependent manner (F(3,39) 5 86.0, P , 0.001). Although 10% was insufficient to produce heat hyperalgesia, both 50% and 90% evoked substantial decrease in HPT from 40.9 6 0.92˚C in the vehicle condition to 37.1 6 0.47˚C after 50% AITC and 36.8 6 0.50˚C after 90% AITC (Fig. 2D) . Heat pain thresholds were also significantly lower in the 50% and 90% AITC conditions compared with the 10% condition, but no difference was found between 50% and 90% AITC concentrations.
Mechanical hyperalgesia and allodynia
AITC induced dose-dependent mechanical hyperalgesia as evident by increased MPS, including mechanical stimuli in the suprathreshold range, was significantly increased for all AITC concentrations, but no clear dose dependency was evident in the response (Fig. 3A) . However, trends toward higher MPS after 50% and 90% AITC concentration compared with the 10% AITC concentration were evident (P 5 0.051 and 0.099, respectively). The mechanical pain threshold (F(3,39) 5 8.41, P , 0.01) decreased after 50% and 90% AITC administration with approximately two-thirds (Fig. 3B) . Although all AITC concentrations evoked significant decreases in MPT with respect to the vehicle, 50% and 90% AITC concentration yielded significantly further decreases compared with 10% AITC concentration (P , 0.05). The WUR to pinprick pain stimuli was unaffected by AITC (F(3,39) 5 1.34, P . 0.05, data not shown). AITC induced significant dose-dependent allodynia to brush strokes (F(3,39) 5 15.8, P , 0.001). For 10% AITC concentration, 9/14 subjects reported allodynia for 50% 11/14 reported it, and for 90% 13/14 reported it. Again, all AITC concentrations induced significant allodynia compared with the vehicle, but 50% and 90% AITC concentrations induced more pronounced allodynia compared with 10% AITC concentration, whereas no differences were present between 50% and 90% AITC concentration. The brush-evoked allodynia was always perceived as nonpainful in normal intact skin on the volar forearm treated with the vehicle. Notably, most subjects spontaneously reported pain associated with gentle wiping of the skin immediately next to the application areas treated with 50% and 90% AITC concentration, when residual solution was removed from the application site. This indicates that although not quantified in this study, secondary allodynia to innocuous touch was evoked. For a comparative overview of the somatosensory aberrations induced by the AITC, see Fig. 4 . 
Neurogenic inflammatory response
All concentrations of AITC induced robust neurogenic inflammation for mean (F(3,39) 5 38.6, P , 0.001) and peak values (F(3,39) 5 34.1, P , 0.001). Clear dose-response relationships were evident for these parameters, although no significant differences were detected between 50% and 90% AITC concentrations for both mean and peak perfusion ( Fig. 5A  and B) . Notably, all AITC concentrations also induced a secondary inflammatory response known as "axon-reflex-flare" (F (3,39) 5 56.8, P , 0.001). The size of this response was also dose dependent with the 90% AITC concentration inducing a larger axon-reflex-flare than the 10% AITC concentration (P . 0.05), with 17.0 6 1.29 cm 2 vs 13.0 6 1.87 cm 2 , respectively (Fig. 5C) . For primary erythema measured by spectroscopy, there was only an effect of time (F(2,24) 5 131.3, P , 0.001) but not for concentration (F(2,24) 5 2.56, P 5 0.099) nor was there an effect of concentration 3 time interaction. Post hoc testing showed that erythema increased following all AITC concentrations and then decreased considerably when measured approximately 64 hours after the initial AITC exposures, although the erythema still remained detectable (P , 0.01). At 64 hours, there was generally no visually perceptible inflammation in the AITC-treated area (Fig. 5D) . For pigmentation, no significant changes occurred at group level for neither time (F (2,24) 5 0.86, P 5 0.44) nor concentration (F(2,24) 5 0.19, P 5 0.44). However, slight but visually discernable hyperpigmentation occurred in 6/14 subjects after 50% AITC concentration and 8/14 after 90% AITC concentration, indicating poor resolution for the applied type of colorimetry quantification of pigmentation (Fig. 5E) . This hyperpigmentation generally resolved within 1 to 2 weeks after the study start.
Discussion
This study showed that 5 minutes topical application of AITC (mustard oil) produces pain and somatosensory sensitization in a dose-dependent manner in healthy human skin. The model evoked robust mechanical hyperalgesia, allodynia, heat hyperalgesia, and neurogenic inflammation. Notably, no significant additional sensitization and pain were achieved when using 90% AITC concentration compared with 50% AITC, indicating a ceiling effect. Based on this study, AITC concentrations of .10% and #50% are likely ideal for elicitation of robust sensory pain symptomatology, while minimizing unnecessary exposure.
Evoked pain intensity and quality
AITC induced dose-dependent, predominantly burning pain, conceivably corresponding to its activation of TRPA1-expressing C-nociceptors in the epidermis. This is well aligned with a previous paper by Koltzenburg et al. (1992) reporting very similar finding related to chemogenically induced pain and pain quality for 100% (pure) AITC applied to a smaller area (2 3 2 cm) for 5 minutes. The predominant burning sensation is also in line with additional previous evidence. 37, 49 Notably, the relatively rapid onset (1-3 minute) of pain after topical administration has previously been observed, 38 corresponding to the temporal profile observed in this study. The AITC model works noticeably faster than topical capsaicin (a TRPV1-agonist), a feature likely related to the fact that it is a smaller and more soluble molecule. Notably, the topical capsaicin model has been extensively used as a TRPV1-pain and inflammation-specific model in early pharmaceutical proof-ofconcept studies for drugs developed for various clinical conditions involving TRPA1. 64 
Thermal sensory sensitivity
AITC did not induce changes in the detection of innocuous cold and warmth, indicating that afferent units conveying these sensations, within the detection threshold range, are likely TRPA1 negative. This corresponds to the prevailing notion of these fibers being myelinated cold Ad-fibers and warmthselective C-fibers, respectively.
14 Although the effect of AITCinduced TRPA1-activation on thermal detection thresholds has not previously been assessed, these results do correspond to findings stemming from the trans-cinnamaldehyde model, which similarly have no or very limited effects on thermal detection thresholds. 2, 58, 61 On the contrary, CPT was decreased by the 90% AITC concentration signifying cold hypoalgesia and a similar, but insignificant trend was observed for the 50% solution. This observation has previously been made for irritants inducing burning pain, for instance capsaicin and trans-cinnamaldehyde, and it has been suggested that this could be a consequence of the pleasantness or relieve associated with cold counter stimulation on the affected skin. It is paradoxical that both TRPA1-agonists, transcinnamaldehyde and here AITC, induce cold hypoalgesia and burning pain, 58, 67 given that TRPA1 has previously been implicated in cold pain sensation. 19, 32, 51 Cold pain is hypothesized to rely on a common nociceptive pathway for both nociceptive heat and cold along with simultaneous activation of innocuous cold Ad-fibers. It has been suggested that TRPA1-positive afferents may mediate the burning component of noxious cold. 18, 58 However, recent evidence indicates that TRPA1 is-by no means-selective to cold pain sensation, 24, 28, 46, 64, 84 and that the channel acts more as a general transducer and amplifier to certain noxious and pruritic stimuli. 35 Last, the evidence implicating TRPA1 in cold pain sensation is almost entirely derived from rodent studies and because peptidergic nociceptors in humans and rodents do exhibit notable dissimilarities, preclinical findings are not necessarily fully transferable. 74 Dose-dependent heat hyperalgesia, as evident from increased HPT, was provoked by AITC. Notably, both 50% and 90% AITC reduced the HPT to 37˚C, ie, only approximately 2.5˚C higher than the heat Figure 4 . Z-score plot of AITC-evoked sensitization. Z-transformed sensory changes evoked by AITC relative to the vehicle condition for thermal and mechanical assessments. AITC, allyl isothiocyanate; ALL, dynamic mechanical allodynia; CDT, cold detection threshold; CPT, cold pain threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; HPT, heat pain threshold; WDT, warmth detection threshold.
detection threshold in the vehicle-treated skin. Heat hyperalgesia is conceivably evoked by primary sensitization of fibers responsible for conveying heat pain around the pain threshold territory, ie, C-and Ad-nociceptors. 44, 52 After TRPA1 activation by AITC, these units respond at temperatures normally insufficient in evoking action potentials and perhaps even at temperatures below those of the innervated skin in situ. Given the estimated 65% coexpression of TRPA1/TRPV1 on peptidergic nociceptive fibers in rats, 34 TRPA1-induced heat hyperalgesia, and perhaps cold hypoalgesia, is likely produced through same subpopulation of fibers that mediate these features in the capsaicin model. www.painjournalonline.com 1729
Mechanical hyperalgesia and dynamic allodynia
AITC induced dose-dependent decreases in MPT and corresponding increases in pain in response to mechanical suprathreshold pain stimuli (increased MPS), although no differences were present between the 3 AITC concentrations for the latter outcome parameter, even when comparisons were conducted with the LSD test. Prolonged mechanical hyperalgesia has previously been described following a 5-minute application of 100% AITC; however, in that study the secondary hyperalgesic area was mapped with a single 23 g von Frey filament, 38 contrasting the present quantification of primary hyperalgesic severity. Normal perception of pinprick pain is thought to primarily reflect type-1 Ad2, and to a lesser extent, PmC-fiber input. 48, 78 The primary hyperalgesia to pinprick stimuli observed in this study could reflect either peripheral sensitization of the aforementioned mechanoreceptive units or perhaps more likely, sensitization occurring at the level of the spinal dorsal horn (central sensitization). 43 In favour of a central mechanism, a previous microneurography study found that PmC-fibers were not sensitized after AITC application. 38, 75 Mechanistically, the aforementioned sensitization would likely be evoked by activation of TRPA1-positive nociceptive peripheral afferent C-fibers 81 and subsequent effects on the spinothalamic tract second-order nociceptive neurons in the dorsal horn. 77 These central neurons, in turn, receive convergent input from capsaicin-insensitive Ad-nociceptors, thus mediating an increased sense of mechanically evoked pricking pain (pinprick hyperalgesia). 42, 77 This explanatory model of centrally mediated sensitization could also explain the pronounced, dose-dependent AITC-induced elicitation of allodynia which has also previously been observed lasting for at least 30 minutes after a 5-minute application of 100% AITC. 38 For allodynia thickly myelinated low-threshold Ab-afferents, rather than Ad-fibers, normally mediating the sense of light touch, would converge onto the nociceptive dorsal horn neurons after the preceding AITC-induced nociceptor barrage and produce the sensations of brush-evoked pain. 42, 43, 81 This explanation is well aligned with the fact that a previous paper on AITC-induced hyperalgesia in humans reported significant secondary hyperalgesia (an aspect of sensitization not quantified in this study), which is recognized to be a centrally mediated phenomenon affecting Ad-(pinprick hyperalgesia) and Ab-fibers (stroke-evoked allodynia). The WUR for pinprick stimuli was unaffected by the AITC provocations, which is in line with the findings in capsaicin-induced hyperalgesic skin. 50 Pinprick hyperalgesia and the itch-related phenomena of hyperknesis and alloknesis, but not allodynia, have previously been reported after use of trans-cinnamaldehyde in humans, 2, 58, 61 but in this study only 1 subject reported a sensation of itch, conceivably because of the high levels of pain and because pruriceptive units were not activated with sufficient selectivity. Lastly, both allodynia and hyperalgesia are very well-studied characteristics of the capsaicin model, which at least in part, activates a subpopulation of nociceptive fibers coexpressing TRPA1, and thus also recruited by AITC administration.
Neurogenic inflammatory response
It is suggested that the primary cause of the herein observed acute inflammation is predominantly neurogenic in origin due to 3 observations; (1) the secondary flare extended several centimeters away from the application area, (2) the flare developed within minutes, (3) there was no sign of exudation (lack of wheal reactions), indicating that mast cell degranulation did not occur. The neurogenic inflammatory response is thought to primarily represent an efferent function of CMi-fibers. 13, 73 With their large terminal aborizations and capacity to release eg, the vasodilatory calcitonin gene-related peptide, this subpopulation of afferent fibers can elicit neurogenic flare significantly beyond the area where an irritant substance is applied. 72, 73, 76 Animal studies have shown that capsaicin-induced desensitization only inhibits acute, but not prolonged TRPA1-mediated inflammation and that antihistamines has no anti-inflammatory effect, 7,30 whereas a human microneurography study has shown that the majority of CMi-fibers are capsaicin responsive (and thus TRPV1 positive). Taken together, this may suggest that AITC produces inflammation through parallel neurogenic and immunological mechanisms; the initial inflammatory response being predominantly neurogenic through CMi-activation and the prolonged primary inflammation measured by spectrometry being primarily immune-driven. This further raises the question of to which extent TRPA1 is an independent nociceptive transducer in human skin (see section below). No differences were observed on primary neurogenic flare or axon-reflex-flare between 50% and 90% AITC concentration, despite assessment with the LSD test, likely indicative of a ceiling effect of either calcitonin gene-related peptide release, vascular responsiveness to the said neuropeptide or ceiling associate with the FLPI technique. A number of previous human studies using the TRPA1-agonist trans-cinnamaldehyde have found a similar neurogenic flare pattern, 58, 61 suggesting that TRPA1 is expressed on a substantial proportion of CMi-fibers.
TRPA1 as an independent nociceptive transducer
TRPA1 has been proposed to play a detrimental role in the pathoetiology of numerous disorders, including neuropathic pain, 9 chronic inflammatory skin diseases, 59 irritable bowel disorders, 41 migraine, 11 and arthritis. 29 Notably, aberrant TRPV1 signalling has also been suggested to be involved in many of these conditions, and there is evidence of structural and functional TRPA1/TRPV1 colocalization. However, although TRPA1 is certainly a TRPV1 independent molecular nociceptive/chemoreceptive transducer, it is unclear whether there is a phenotypically significant subpopulation of afferent fibers that are TRPA1 expressing, but TRPV1 negative in humans. A recent study showed that TRPA1-induced hyperalgesia relies entirely on TPRV1 expression, 22 contradicting the conventional notion of some functional independence. 10, 31 As previous studies have almost exclusively been conducted in rodents, it would be relevant to assess whether TRPA1-induced pain and inflammation is inducible in human skin where TRPV1-positive nociceptors have been defunctionalized, eg, by preapplication of high concentration of capsaicin. 3, 27 Using such defunctionalization of TRPV1-fibers in humans, it has recently been shown that a PAR2-mediated itch provocation, principally relying on coactivation of TRPA1, is abolished when TRPV1-positive fibers have been ablated by prolonged 8% capsaicin application. 3 This seems to indicate that at least the entire subpopulation of pruriceptive nociceptors characterized by PAR2/TRPA1-expression is also TRPV1 positive. In most aspects, the observed pain response for AITC is similar to that known from topical capsaicin application. 33, 38, 61 However, likely associated with differences in skin penetration rates of these 2 chemical substances, AITC evokes pain and hyperalgesia more rapidly than capsaicin. Several limitations adhere to the results of this study: (1) Although steps were taken to assure blinding of subjects and the investigator, it was difficult to avoid unmasking of the vehicle condition given that no visible flare or no pain was present as opposed to the AITC conditions. (2) Although dose-response features were assessed in participants of both sexes, the study was not designed to detect potential sex differences, which are well established to exist in several experimental pain models and clinical pain conditions. 55, 65 Future studies on TRPA1-induced pain and sensitization should address this issue for this particular type of pain provocation. (3) Although sensory testing was conducted after the spontaneously evoked pain had subsided, it cannot be excluded that low-intensity discharges within the area continued and/or that pain sensitization could have been rekindled or maintained by the somatosensory testing on the treated skin. However, to minimize this possibility, the assessment of HPTs was conducted at the very end of each assessment panel for each applied solution.
Conclusion
This study shows that topical AITC (mustard oil) is an effective, safe, and easily applicable, human surrogate model of TRPA1-evoked pain, hyperalgesia, and neurogenic inflammation. For both evoked pain and most somatosensory sensitization parameters, the model produces dose-dependent responses, with no significant additional effects beyond a concentration of 50%. To minimize risks and irritant exposure, future studies should therefore use AITC concentrations .10% to #50%. The model is suitable for experimental pain studies in healthy controls or patients, eg for pain sensitivity profiling, and could be particularly useful in pharmacological proof-of-concept studies of TRPA1-antagonists, analgesics, and anti-inflammatory drugs.
